Introduction {#Sec1}
============

Acute kidney injury (AKI) is a common and serious process that occurs in a wide variety of clinical settings. Lack of early AKI biomarkers has impeded timely interventions to ameliorate the downstream effects of AKI and has hindered further clinical investigation of therapies that are effective in animal studies.

Neutrophil gelatinase-associated lipocalin (NGAL) is a promising biomarker for early detection of AKI \[[@CR1]\]. Several studies have shown serum and urine NGAL to be useful early markers for AKI, particularly when the timing of the renal insult is known, such as post-cardiac surgery and radiocontrast exposure \[[@CR2], [@CR3]\]. However, its performance in a more general intensive care unit (ICU) setting has not been as well described. Urine NGAL was found to be a useful early marker for development of AKI in pediatric ICU patients (AuROC 0.78) \[[@CR4]\], whereas serum NGAL was a highly sensitive but nonspecific predictor of AKI in critically ill children with septic shock (AuROC 0.68) \[[@CR5]\]. We hypothesized that plasma NGAL would also be an early biomarker of AKI in an unselected population of critically ill adults.

The main objective of the study was to estimate the diagnostic accuracy of plasma NGAL (pNGAL) in an adult general ICU for the early detection of AKI. Additional objectives were to evaluate pNGAL as a biomarker for renal replacement therapy (RRT) use and mortality in the ICU, as well as to explore the relationship between pNGAL, AKI severity and overall severity of illness.

Concise methods {#Sec2}
===============

Study design and setting {#Sec3}
------------------------

This was a prospective observational study of consecutive adult patients admitted to a general ICU from January to July 2007. Patients were enrolled within 24 h of ICU admission; informed consent was obtained from the patient surrogate. Detailed methods are described in ESM File 1.

Clinical and laboratory data collection {#Sec4}
---------------------------------------

Multiple data elements were collected for each patient and included demographics, co-morbidities, admission diagnosis, severity of illness scores, RRT provision and ICU mortality. Clinical charts were reviewed for a history of exposure to potential nephrotoxins and use of diuretics in the ICU.

Laboratory data were measured daily as part of routine patient care. Blood samples for NGAL were collected daily from ICU admission for up to 4 days. Reasons for not collecting blood samples for NGAL for all 4 days included death, ICU discharge and ongoing RRT.

Definition of acute kidney injury {#Sec5}
---------------------------------

AKI was defined using the creatinine and urine output criteria of the RIFLE (Risk-Injury-Failure-Loss-Endstage renal disease) classification \[[@CR6]\]. Baseline renal function was defined as the lowest known SCr value during the preceding 3 months. For patients without known prior SCr, the baseline serum creatinine was estimated by solving the MDRD equation \[[@CR6], [@CR7]\].

Patients were classified daily using the RIFLE criteria. RIFLE-initial refers to their RIFLE class on the first day of AKI. RIFLE-max refers to the worst RIFLE class reached by a patient during his ICU stay. For AKI patients, renal status at ICU discharge was defined as follows: Complete recovery if discharge SCr was \<150% of baseline; partial recovery if discharge SCr was 150--199% of baseline; non-recovery if discharge SCr was ≥200% of baseline or still receiving RRT.

Sampling and measurement of NGAL {#Sec6}
--------------------------------

Blood samples for NGAL were collected daily, and samples were processed within 1 h from time of collection. We centrifuged samples at 3,500×*g* for 10 min and stored the supernatant in equal volumes at −80°C until measurement. Plasma NGAL (pNGAL) was measured using the Triage® NGAL Test (Biosite Inc, San Diego, CA), a point-of-care, fluorescence-detected immunoassay. We measured pNGAL in 873 blood samples (median 3 samples/patient). Laboratory investigators were blinded to sample sources and clinical information until the end of the study. For comparative purposes, pNGAL was measured in banked anti-coagulated plasma of apparently healthy donors (*n* = 120).

Statistical analysis {#Sec7}
--------------------

Continuous variables are expressed as mean ± standard deviation or median (interquartile range) and compared between any two groups using t-test or the Mann--Whitney *U* test, and among three or more groups using analysis of variance (general linear models with adjustment for multiple comparisons) or the Kruskal--Wallis test, where appropriate. Categorical variables are expressed as proportions and compared with the chi-square test or Fisher\'s exact test.

Diagnostic characteristics of pNGAL were evaluated with receiver-operating characteristic (ROC) curves. The primary outcome of interest was prediction of AKI. Based on prior studies \[[@CR4], [@CR8]\], for our primary analysis we defined an event as AKI occurring within 48 h of first pNGAL measurement. Secondary outcomes included RRT use, ICU mortality, and their composite endpoint.

After seeing the relationship between pNGAL and these scores, we also performed a post hoc covariate analysis using multiple logistic regression to determine the independent predictive ability of the first pNGAL for AKI within 48 h. The following covariates were considered: age, APACHE, SAPS and SOFA scores. For all analyses, two-tailed *P* values \<0.05 were considered significant. Statistical analyses were conducted using SPSS 15 (SPSS Inc., Chicago, IL) and MATLAB 7.5.0 (The MathWorks, Inc., Natick, MA).

Results {#Sec8}
=======

Patient demographics {#Sec9}
--------------------

We enrolled 307 consecutive incident patients to an adult medical-surgical ICU. We excluded 5 patients with endstage renal disease on chronic RRT and 1 patient for uninterpretable NGAL result, leaving 301 patients for analysis. Patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. Two hundred twenty patients (73%) had an eGFR \<90 ml/min/1.73 m^2^, of whom 20 (6.6%) had an eGFR \<60 ml/min/1.73 m^2^. The most common diagnostic categories for ICU admission were Neurologic, Respiratory, Cardiovascular, Trauma and Gastrointestinal, accounting for 89% of admissions. Median ICU length of stay was 7 days (IQR 3, 13). Crude ICU and hospital mortalities were 17.3 and 25.5%, respectively, and 58 (19.3%) patients met the composite RRT or ICU death endpoint.Table 1Characteristics of the cohort by presence or absence of acute kidney injury (AKI)AllNon-AKIAKI*PN*301168133 Male sex (%)207 (68.8)113 (67.3)94 (70.7)0.53Age (years)64 (45,74)58 (37, 70.5)69 (61, 76.5)\<0.001Body weight (kg)76.5 ± 12.375.6 ± 13.177.7 ± 11.20.16Baseline creatinine (mg/dl)0.9 (0.8, 1.0)0.9 (0.8, 1.0)1.0 (0.8, 1.0)0.035Diabetes (%)47 (15.6)16 (9.5)31 (23.3)0.001Chronic kidney disease (%)20 (6.6)8 (4.8)12 (9.0)0.16Patient type Medical (%)164 (54.6)85 (50.6)79 (59.4)0.13 Elective surgery (%)25 (8.3)14 (8.3)11 (8.3)1.00 Emergency surgery (%)112 (37.1)69 (41.1)43 (32.3)0.15Admission diagnosis Neurologic (%)90 (29.9)66 (39.3)24 (18)\<0.001 Respiratory (%)57 (18.9)24 (14.3)33 (24.8)0.026 Cardiovascular (%)51 (16.9)23 (13.7)28 (21.1)0.12 Trauma (%)49 (16.3)31 (18.5)18 (13.5)0.27 Gastrointestinal (%)22 (7.3)10 (6.0)12 (9.0)0.374ICU admission SAPS II41 ± 1538 ± 1545 ± 14\<0.001 APACHE II18 ± 716 ± 720 ± 7\<0.001 SOFA5 (5, 7)5 (4, 6)5 (5, 8)\<0.001 Creatinine (mg/dl)1.0 (0.8, 1.4)0.9 (0.8, 1.1)1.3 (1.0, 2.0)\<0.001 Plasma NGAL (ng/ml)117.0 (68.2, 213.8)82.0 (49.7, 134.1)185 (95.4, 403.5)\<0.001 Potential nephrotoxins (%)38 (12.6)15 (8.9)23 (17.3)0.036 Use of vasopressors (%)102 (33.9)35 (20.8)67 (50.4)\<0.001ICU course Diuretics (%)157 (52.2)65 (38.7)92 (69.2)\<0.001 Sepsis (%)115 (38.2)49 (29.2)66 (49.6)\<0.001Outcome ICU mortality (%)52 (17.3)15 (8.9)37 (27.8)\<0.001 RRT or ICU mortality (%)58 (19.3)15 (8.9)43 (32.3)\<0.001 ICU length of stay (days)7 (3, 13)5 (3, 10)9 (5, 15)\<0.001 ICU LOS: survivors (days)7 (3, 13)6 (3,10.5)9 (5,15.8)\<0.001 ICU LOS: nonsurvivors (days)7 (4, 13)5 (2,7)9 (4,16)0.019Body weight, SAPS II and APACHE II are expressed as mean ± standard deviation. All other continuous variables are expressed as median (IQR)

Acute kidney injury {#Sec10}
-------------------

Of 301 patients, 133 (44%) had AKI during their ICU stay; 90 patients had AKI within 24 h of ICU admission, while 43 developed it later during their ICU stay (median 3rd day, IQR 2--5) (see ESM File 1, ESM Table 1). RIFLE-initial class was Risk in 92 patients (30.6%), Injury in 17 (5.6%) and Failure in 24 (8.0%). Progression of AKI to a worse RIFLE class was seen in 37 patients (28% of AKI patients). The maximum RIFLE class reached (RIFLE-max) was Risk in 57 patients (18.9%), Injury in 42 (14%) and Failure in 34 (11.3%). Fifteen patients (5%) were treated with RRT in the ICU. AKI patients were older, less likely to have a neurologic diagnosis and more likely to have a respiratory diagnosis on ICU admission, had higher APACHE II, SAPS II and SOFA scores, and higher baseline and admission SCr values. They were more likely to have had exposure to potential nephrotoxins prior to their ICU admission, and to have received diuretics during their ICU stay. Sixty-six AKI patients (49.6%) fulfilled criteria for sepsis during their ICU stay, compared to 49 (29.2%) of non-AKI patients (*P* \< 0.001), whereas 83 AKI patients (62.4%) fulfilled criteria for SIRS or sepsis during their ICU stay, as compared to 80 (47.6%) of non-AKI patients (*P* = 0.014).

AKI patients had a higher crude ICU mortality (27.8% vs. non-AKI 8.9%, *P* \< 0.001) and longer ICU length of stay \[median 9 days vs. 5 days (non-AKI), *P* \< 0.001\]. Sixty-four patients (48% of AKI patients) had complete recovery of renal function, with a SCr at time of ICU discharge that was \<150% of baseline; an additional 27 AKI patients (20%) had partial renal recovery.

NGAL in AKI and non-AKI {#Sec11}
-----------------------

The median first pNGAL in the study population was 117.0 (IQR 68.2, 213.8) ng/ml, which was significantly higher than 61.2 (IQR 60.0--78.5) ng/ml observed in apparently healthy adults (*P* \< 0.001). Even ICU patients without AKI had significantly higher pNGAL levels (82.0 ng/ml, IQR 49.7, 134.1) compared to healthy adults (*P* = 0.004). A summary of first pNGAL values in the study population is shown in Fig. [1](#Fig1){ref-type="fig"}. Compared to non-AKI patients, pNGAL values were higher among patients who already had AKI at the time of first pNGAL measurement (213.7 ng/ml, IQR 110.4, 553.3; *P* \< 0.001 vs. non-AKI), as well as in patients who developed AKI within 48 h (209.0 ng/ml, IQR 101.4, 268.2; *P* \< 0.001 vs. non-AKI). Patients who developed AKI within 24 h had a median pNGAL of 225.3 ng/ml (IQR 163.0, 279.5; *P* \< 0.001 vs. non-AKI), whereas those who developed it within 24--48 h had a median pNGAL of 140.7 ng/ml (IQR 95.8, 218.3; *P* = 0.13 vs. non-AKI). In contrast, patients who developed AKI after \>48 h had pNGAL similar to non-AKI patients (79.8 ng/ml, IQR 52, 143.9; *P* = 0.81). The proportion of AKI patients was higher with progressive quartiles of first pNGAL measurement (see ESM file 1, ESM Fig. 1, *P* \< 0.001).Fig. 1Plasma NGAL values by timing of AKI. Values represent first plasma NGAL specimen. \**P*-value refers to comparison with Non-AKI group

A graphical representation of the kinetics of pNGAL is shown in Fig. [2](#Fig2){ref-type="fig"}. For AKI patients, the *X*-axis shows AKI Day \[[@CR4], [@CR8]\]. AKI Day 0 is the day in which the diagnosis of AKI was made based on the RIFLE criteria. One day prior to AKI, pNGAL was higher in these patients compared to non-AKI, and increased further on AKI Day 0. Patients who never developed AKI had comparatively lower pNGAL values without notable variation during the study period (*P* \< 0.001 at each time point).Fig. 2Mean plasmaNGAL concentrations at various timepoints in patients with (*solid squares*) and without (*open squares*) acute kidney injury (AKI). For AKI patients, the *X*-axis shows AKI Day. AKI Day 0 is the day in which the diagnosis of AKI was first made based on the RIFLE criteria. The *green bar* indicates the days when there is AKI. For non-AKI patients, the *X*-axis represents consecutive NGAL collection days. Patients who never developed AKI had comparatively lower plasma NGAL values without notable variation (*P* \< 0.001 at each time point). *Error bars* are SEM

NGAL and prediction of clinical outcome {#Sec12}
---------------------------------------

Performance characteristics of pNGAL for prediction of AKI and secondary outcomes are shown in Fig. [3](#Fig3){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}. Plasma NGAL was a good diagnostic marker for AKI development within the next 48 h from the first measurement (Fig. [3](#Fig3){ref-type="fig"}), with an area under ROC (AuROC) of 0.78 (95% CI 0.65--0.90). Using a threshold value of 150 ng/ml for pNGAL, the sensitivity was 73%, and specificity was 81% (Table [2](#Tab2){ref-type="table"}). Plasma NGAL levels \>150 ng/ml were associated with increased odds of AKI of 11.8 (95% CI 3.5--39.2). Furthermore, pNGAL was also a good predictor for RRT use during the ICU stay (AuROC 0.82, 95% CI 0.70--0.95). However, its performance was comparatively weaker with regards to prediction of AKI occurring within the next 5 days, ICU mortality, and the composite endpoint of RRT and ICU mortality (AuROC 0.67, 0.67 and 0.68, respectively).Fig. 3Receiver operator characteristic (ROC) curve for plasma NGAL. The area under the ROC is 0.78 (95% CI 0.65--0.90), demonstrating a good performance for the diagnosis of AKI within the next 48 hTable 2Test characteristics of plasma NGAL for acute kidney injury and clinical outcomesROC analysisAt cutoff of 150 ng/mlAuC ROC (95% CI)Sensitivity (95% CI)Specificity (95% CI)PPV (95% CI)NPV (95% CI)AKI within 48 h0.78 (0.65--0.90)0.73 (0.45--0.92)0.81 (0.75--0.86)0.24 (0.13--0.39)0.97 (0.93--0.99)AKI within 5 days0.67 (0.55--0.79)0.46 (0.27--0.67)0.80 (0.74--0.86)0.26 (0.14--0.41)0.91 (0.85--0.95)RRT within ICU stay0.82 (0.70--0.95)0.87 (0.60--0.98)0.65 (0.60--0.71)0.12 (0.06--0.19)0.99 (0.96--1.00)ICU mortality0.67 (0.58--0.77)0.60 (0.45--0.73)0.68 (0.61--0.73)0.28 (0.20--0.37)0.89 (0.84--0.93)RRT + ICU mortality0.68 (0.59--0.77)0.60 (0.47--0.73)0.68 (0.62--0.74)0.31 (0.23--0.41)0.88 (0.82--0.92)

We also described the cohort with respect to the ascertained threshold pNGAL value (see ESM File 1, ESM Table 2). The findings are similar to Table [1](#Tab1){ref-type="table"}, reflecting the association between AKI and elevated pNGAL levels. Patients with first pNGAL \>150 ng/ml were older, were more likely to have CKD, have higher APACHE II and SOFA scores and SCr on ICU admission, and were more likely to have had exposure to potential nephrotoxins. Over 70% of these patients had AKI during their ICU stay. Also, this group had higher RRT use (11.7%) and ICU mortality (27%). The duration of AKI among survivors was longer in patients with first pNGAL \>150 ng/ml versus those with first pNGAL \<150 ng/ml (4 days, IQR 2,7 vs. 2 days, IQR 1,6, respectively, *P* = 0.013).

NGAL and severity of illness and AKI {#Sec13}
------------------------------------

All blood specimens were used to calculate peak and mean pNGAL values \[[@CR4]\]. Peak pNGAL concentrations increased with worsening severity of AKI (Table [3](#Tab3){ref-type="table"}). There was a similar relationship between mean pNGAL levels and RIFLE-max class (Non-AKI 71.4 ng/ml, IQR 43.9, 124.3; Risk 139.9 ng/ml, IQR 67.4, 185.0; Injury 161.6 ng/ml, IQR106.9--286.1; Failure 522.0 ng/ml, IQR 288.2--1061.8; *P* \< 0.001 by Kruskal--Wallis test). Peak pNGAL levels also correlated well with RIFLE-max class (*R* = 0.554, *P* \< 0.001). Patients were further grouped according to APACHE II, SAPS II and SOFA scores, and by presence of sepsis. In general, pNGAL levels were higher among patients with higher severity of illness scores, whether expressed as peak pNGAL (Table [3](#Tab3){ref-type="table"}), mean pNGAL or first pNGAL levels (data not shown). There were weak but highly statistically significant correlations between peak NGAL levels and APACHE II (*R* = 0.287, *P* \< 0.001), SAPS II (*R* = 0.215, *P* \< 0.001) and SOFA scores (*R* = 0.289, *P* \< 0.001). There was no significant difference in pNGAL among patients with and without sepsis or SIRS (Table [3](#Tab3){ref-type="table"}).Table 3Peak plasma NGAL values by patient subgroupsCategoryMean ± SDMedian (IQR)*P*RIFLE-max NonAKI162.1 ± 302.8102.4 (67.4, 147.5)\<0.001 Risk229.6 ± 199.4171.4 (101.9, 281.7) Injury332.4 ± 314.2214.9 (137.5, 419.5) Failure803.8 ± 529.2620.3 (406.4, 1366.4)APACHE II ≤Median219.0 ± 361.0117.4 (77.9, 193.9)\<0.001 \>Median329.8 ± 387.8173.0 (89.4, 407.8)SAPS II ≤Median223.1 ± 354.7123.4 (76.0, 224.8)0.005 \>Median322.8 ± 395.1152.8 (90.2, 395.4)SOFA ≤Median248.1 ± 390.5120.9 (77.0, 214.8)0.001 \>Median310.5 ± 352.1175.2 (100.4, 401.9)Sepsis No264.9 ± 394.0133.2 (80.0, 244.4)0.334 Yes281.2 ± 350.2137.5 (86.6, 373.8)Sepsis or SIRS No265.6 ± 335.7140.9 (82.1, 255.0)0.717 Yes275.8 ± 410.3132.2 (79.2, 283.3)Median APACHE II score = 18Median SAPS II score = 40Median SOFA score = 5

Table [4](#Tab4){ref-type="table"} shows the results of posthoc univariate and multivariate logistic regression analysis using age, APACHE II scores and first pNGAL concentration as independent variables to predict AKI within 48 h of admission. Age was not significant in either the univariate or multivariate model, whereas APACHE II was marginally significant, and NGAL was highly significant. The adjusted odds ratio for pNGAL did not depend significantly on which ICU severity score was used (APACHE II, SAPS II or SOFA) in the model; the best model was that using the APACHE II.Table 4Univariate and multivariate analysis of plasma NGAL for prediction of acute kidney injury (AKI) within 48 hUnivariateMultivariateOR (95%CI)*P*OR (95%CI)*P*Age1.003 (0.977--1.030)0.8320.987 (0.959--1.015)0.360APACHE II1.074 (0.999--1.154)0.0521.084 (1.000--1.174)0.050log (pNGAL)4.989 (1.496--5.652)0.0023.059 (1.509--6.201)0.002The odds ratio for each independent variable is a point estimate computed from the model coefficient (beta). The adjusted odds ratio for pNGAL did not depend significantly on which ICU severity score was used (APACHE II, SAPS II or SOFA) in the model; the best model was that using the APACHE II

Discussion {#Sec14}
==========

We conducted a prospective study to evaluate plasma NGAL for the early diagnosis of AKI in a heterogeneous adult population. The key findings of this study are the following: first, 44% of ICU patients had AKI during their ICU stay, and nearly 30% had this within 24 h of admission, consistent with prior studies \[[@CR9]\]. Second, plasma NGAL levels are significantly higher in ICU patients compared to healthy adults and are higher in AKI patients compared to non-AKI patients. Third, pNGAL was a good independent predictor for the development of AKI within the next 48 h (AuROC 0.78, 95% CI 0.65--0.90) and for RRT use during the ICU stay (AuROC 0.82, 95% CI 0.70--0.95). Fourth, pNGAL correlated with severity of AKI, as well of severity of illness.

Human NGAL is a 25-kDa protein covalently bound to gelatinase and is one of the most upregulated transcripts in the kidney very early after acute injury \[[@CR1]\]. To our knowledge, this prospective study is the first to examine plasma NGAL in a heterogeneous adult population. The AuROC in our study is highly consistent with that reported in 19 studies across different AKI settings (Haase et al., AJKD 2009, in press), but slightly lower than that reported in pediatric studies \[[@CR10]--[@CR12]\]. This is related to multiple factors, including the presence of co-morbid conditions and underlying chronic kidney disease (CKD) in our adult ICU population compared to children. These conditions may lead to elevation of NGAL levels independent of renal injury, which could confound the predictive ability of pNGAL for AKI \[[@CR13]--[@CR15]\]. Moreover, unlike surgery or radiocontrast exposure, neither the timing nor severity of the renal insult is known in a general ICU. In the setting of cardiopulmonary bypass, for example, there is a temporally predictable injury to the kidneys, and surrogate markers of the severity of injury such as cross-clamp time are available. In contrast nephropathy, the amount of administered radiocontrast may be a surrogate for the degree of renal injury. In comparison, although pNGAL could be measured in critically ill patients within the first 24 h of admission to the ICU, this may not necessarily be the first 24 h of their disease process. Furthermore, in the medical ICU, the kidney is likely to receive "multiple hits" of varying severity, quite different from the seemingly "single hit" model encountered in most surgical situations.

Both serum and urine NGALs (uNGAL) have been studied as markers for AKI in critically ill pediatric patients. Serum NGAL was a highly sensitive but nonspecific predictor of AKI in children with septic shock (AuROC 0.68) \[[@CR5]\]. In a heterogeneous pediatric ICU population, uNGAL was a useful early marker for development of AKI within 48 h, with AuROC 0.78 \[[@CR4]\]. Similar to our own findings, mean and peak uNGAL increased with worse pediatric RIFLE class. They also observed a weak correlation between Pediatric Risk of Mortality (PRISM) scores and mean and peak uNGAL in AKI patients.

In adults, Makris et al. found uNGAL measured within 24 h from injury to be a useful early AKI marker in critically ill trauma patients, with AuROC of 0.97 \[[@CR2]\]. This situation is analogous to that of surgery or contrast nephropathy, where the timing of renal insult is clearly defined. In addition, the AKI group was significantly older than the non-AKI group (median age 60 vs. 32 years, respectively), and this may have contributed to the relatively high AuROC in this study. In a recent single-center study in critically ill adults, uNGAL was shown to have moderate predictive utility for the development of AKI, although its additional contribution to conventional clinical risk factors appears limited \[[@CR16]\].

Our study makes an important contribution to the current body of literature on NGAL and AKI. Ours is the first study to prospectively evaluate plasma NGAL in all patients admitted to an adult general ICU, making the results more readily applicable to the usual ICU population. The cohort was followed through the entire ICU stay. This study also utilizes both the SCr and urine output criteria of RIFLE, as recommended by the ADQI group \[[@CR6]\]. Moreover, we used a standardized user-friendly platform; a recent meta-analysis reported better AuROCs with standardized NGAL assays compared to "research-based" ELISA assays (Haase et al., AJKD 2009, in press). Our use of a commercially available platform is also a potential strength, since this would allow other investigators to confirm these findings. Our results show that pNGAL is a useful biomarker even in a population with common co-morbidities, such as diabetes, CKD and exposure to potential nephrotoxins. As such, it complements the original study that recruited a homogenous cohort of children who had no co-morbidities and had normal renal function \[[@CR10]\]. Finally, we demonstrate in adult ICU patients that pNGAL correlates with severity of AKI and critical illness, yet remains an independent predictor for AKI after adjustment for severity of illness. Other investigators have looked at other novel biomarkers for AKI in critically ill adults, including cystatin-C \[[@CR17]\], IL-18 \[[@CR8]\], IL-6 \[[@CR18]\], soluble TNF-receptors (S-TNF-R) \[[@CR19]\], urinary N-acetyl-β-(D)-glucominidase activity (NAG) \[[@CR20], [@CR21]\], kidney injury molecule-1 (KIM-1) \[[@CR20], [@CR21]\] and matrix metalloproteinase-9 (MMP-9) \[[@CR21]\]. Some of these studies looked at either selected high-risk ICU populations \[[@CR17]\] or enrollees in randomized controlled trials \[[@CR8], [@CR18], [@CR19]\]; therefore, the results may not be broadly applicable to the more general population seen in clinical practice.

We acknowledge certain limitations in this study. This study enrolled patients from a single center; data from a multicenter study would be more generalizable. Moreover, nearly 30% of patients in this study already fulfilled criteria for AKI on admission to the ICU. This is consistent with data from a large observational study that showed that AKI occurred in 36% on the day of ICU admission \[[@CR9]\]. This may be an important limitation for any studies on early biomarkers in an unselected adult ICU population.

In summary, plasma NGAL appears to be a useful early marker for the development of AKI in a large heterogeneous adult ICU population, allowing the diagnosis of AKI up to 48 h prior to a clinical diagnosis based on AKI consensus definitions. It is also a good predictor of need for RRT, and correlates with AKI severity and overall severity of illness. Early identification of patients who are likely to develop AKI and those who may require RRT will allow early targeted therapy of these high risk patients with potentially beneficial treatments before significant renal injury occurs.
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